O	0	8	Efficacy
O	9	11	of
O	12	17	first
O	17	18	-
O	18	22	line
B-intervention	23	32	letrozole
O	33	39	versus
B-control	40	49	tamoxifen
O	50	52	as
O	53	54	a
O	55	63	function
O	64	66	of
O	67	70	age
O	71	73	in
O	74	88	postmenopausal
O	89	94	women
O	95	99	with
O	100	108	advanced
O	109	115	breast
O	116	122	cancer
O	122	123	.

O	124	126	To
O	127	134	compare
O	135	138	the
O	139	147	efficacy
O	147	148	,
O	149	151	in
O	152	158	regard
O	159	161	to
O	162	166	time
O	167	169	to
O	170	181	progression
O	182	183	(
O	183	186	TTP
O	186	187	)
O	188	191	and
O	192	201	objective
O	202	210	response
O	211	215	rate
O	216	217	(
O	217	220	ORR
O	220	221	)
O	221	222	,
O	223	225	of
O	226	235	letrozole
O	236	237	(
O	237	243	Femara
O	243	244	;
O	245	253	Novartis
O	254	260	Pharma
O	261	263	AG
O	263	264	;
B-location	265	270	Basel
I-location	271	282	Switzerland
O	282	283	)
O	283	284	,
O	285	287	an
O	288	292	oral
O	293	302	aromatase
O	303	312	inhibitor
O	312	313	,
O	314	318	with
O	319	323	that
O	324	326	of
O	327	336	tamoxifen
O	337	338	(
O	338	345	Tamofen
O	345	346	;
O	347	353	Leiras
O	354	356	OY
O	356	357	;
B-location	358	363	Turku
I-location	363	364	,
I-location	365	372	Finland
O	372	373	)
O	374	376	as
O	377	382	first
O	382	383	-
O	383	387	line
O	388	395	therapy
O	396	398	in
O	399	406	younger
O	407	408	(
B-age	408	409	<
I-age	409	411	70
I-age	412	417	years
O	417	418	)
O	419	422	and
O	423	428	older
O	429	430	(
B-age	430	431	>
I-age	431	432	/
I-age	432	433	=
I-age	433	435	70
I-age	436	441	years
O	441	442	)
O	443	457	postmenopausal
O	458	463	women
O	464	468	with
O	469	477	advanced
O	478	484	breast
O	485	491	cancer
O	491	492	.

B-total-participants	493	497	Nine
I-total-participants	498	505	hundred
I-total-participants	506	511	seven
B-eligibility	512	520	patients
I-eligibility	521	525	with
I-eligibility	526	534	advanced
I-eligibility	535	541	breast
I-eligibility	542	548	cancer
O	549	553	were
O	554	562	randomly
O	563	571	assigned
O	572	574	to
O	575	582	receive
O	583	584	2
O	584	585	.
O	585	586	5
O	587	589	mg
O	590	599	letrozole
O	600	601	(
O	601	602	n
O	603	604	=
O	605	608	453
O	608	609	)
O	610	612	or
O	613	615	20
O	616	618	mg
O	619	628	tamoxifen
O	629	630	(
O	630	631	n
O	632	633	=
O	634	637	454
O	637	638	)
O	639	643	once
O	644	649	daily
O	650	652	in
O	653	654	a
O	655	661	double
O	661	662	-
O	662	667	blind
O	667	668	,
O	669	680	multicenter
O	680	681	,
O	682	695	international
O	696	701	trial
O	701	702	.

O	703	708	Among
O	709	712	the
O	713	726	prospectively
O	727	734	planned
O	735	743	analyses
O	744	748	were
O	749	757	analyses
O	758	760	of
O	761	764	TTP
O	765	768	and
O	769	772	ORR
O	773	775	by
O	776	779	age
O	780	781	(
O	781	782	<
O	782	784	70
O	785	788	and
O	789	790	>
O	790	791	/
O	791	792	=
O	792	794	70
O	795	800	years
O	800	801	)
O	801	802	.

O	803	806	The
O	807	814	results
O	815	817	of
O	818	823	these
O	824	837	prospectively
O	838	845	planned
O	846	854	analyses
O	855	858	are
O	859	867	reported
O	868	872	here
O	872	873	.

O	874	883	Letrozole
O	884	887	was
O	888	890	as
O	891	900	effective
O	901	903	in
O	904	909	older
O	910	924	postmenopausal
O	925	930	women
O	931	932	(
O	932	933	>
O	933	934	/
O	934	935	=
O	935	937	70
O	938	943	years
O	944	946	of
O	947	950	age
O	950	951	)
O	952	954	as
O	955	957	it
O	958	961	was
O	962	964	in
O	965	972	younger
O	973	987	postmenopausal
O	988	993	women
O	994	995	(
O	995	996	<
O	996	998	70
O	999	1004	years
O	1005	1007	of
O	1008	1011	age
O	1011	1012	)
O	1012	1013	.

O	1014	1017	The
B-outcome	1018	1025	overall
I-outcome	1026	1029	ORR
O	1030	1032	in
O	1033	1036	the
O	1037	1042	older
O	1043	1051	subgroup
O	1052	1055	was
O	1056	1069	significantly
O	1070	1076	higher
O	1077	1079	in
O	1080	1088	patients
O	1089	1096	treated
O	1097	1101	with
O	1102	1111	letrozole
O	1112	1113	(
B-iv-bin-percent	1113	1115	38
I-iv-bin-percent	1115	1116	%
O	1116	1117	)
O	1118	1122	than
O	1123	1125	in
O	1126	1134	patients
O	1135	1142	treated
O	1143	1147	with
O	1148	1157	tamoxifen
O	1158	1159	(
B-cv-bin-percent	1159	1161	18
I-cv-bin-percent	1161	1162	%
O	1162	1163	)
O	1163	1164	.

O	1165	1167	In
O	1168	1171	the
O	1172	1179	younger
O	1180	1188	subgroup
O	1189	1191	of
O	1192	1206	postmenopausal
O	1207	1215	patients
O	1215	1216	,
O	1217	1220	the
B-outcome	1221	1225	ORRs
O	1226	1230	were
O	1231	1234	not
O	1235	1248	significantly
O	1249	1258	different
O	1259	1260	(
O	1260	1269	letrozole
O	1269	1270	,
B-iv-bin-percent	1271	1273	26
I-iv-bin-percent	1273	1274	%
O	1274	1275	;
O	1276	1285	tamoxifen
O	1285	1286	,
B-cv-bin-percent	1287	1289	22
I-cv-bin-percent	1289	1290	%
O	1290	1291	)
O	1291	1292	.

B-outcome	1293	1296	TTP
O	1297	1300	was
O	1301	1314	significantly
O	1315	1321	longer
O	1322	1325	for
O	1326	1335	letrozole
O	1336	1340	than
O	1341	1344	for
O	1345	1354	tamoxifen
O	1355	1357	in
O	1358	1362	both
O	1363	1366	age
O	1367	1373	groups
O	1374	1375	(
B-outcome	1375	1382	younger
O	1382	1383	:
O	1384	1393	letrozole
O	1394	1400	median
O	1401	1404	TTP
O	1404	1405	,
B-iv-cont-median	1406	1407	8
I-iv-cont-median	1407	1408	.
I-iv-cont-median	1408	1409	8
I-iv-cont-median	1410	1416	months
O	1416	1417	;
O	1418	1427	tamoxifen
O	1427	1428	,
B-cv-cont-median	1429	1430	6
I-cv-cont-median	1430	1431	.
I-cv-cont-median	1431	1432	0
I-cv-cont-median	1433	1439	months
O	1439	1440	;
B-outcome	1441	1446	older
O	1446	1447	:
O	1448	1457	letrozole
O	1458	1464	median
O	1465	1468	TTP
O	1468	1469	,
B-iv-cont-median	1470	1472	12
I-iv-cont-median	1472	1473	.
I-iv-cont-median	1473	1474	2
I-iv-cont-median	1475	1481	months
O	1481	1482	;
O	1483	1492	tamoxifen
O	1492	1493	,
B-cv-cont-median	1494	1495	5
I-cv-cont-median	1495	1496	.
I-cv-cont-median	1496	1497	8
I-cv-cont-median	1498	1504	months
O	1504	1505	)
O	1505	1506	.

O	1507	1515	Although
O	1516	1519	age
O	1520	1523	was
O	1524	1537	independently
O	1538	1548	prognostic
O	1549	1551	of
O	1552	1555	TTP
O	1555	1556	,
O	1557	1562	there
O	1563	1566	was
O	1567	1569	no
O	1570	1581	significant
O	1582	1588	effect
O	1589	1591	of
O	1592	1595	age
O	1596	1598	on
B-outcome	1599	1602	ORR
O	1603	1605	in
O	1606	1609	the
O	1610	1618	presence
O	1619	1621	of
O	1622	1627	other
O	1628	1635	factors
O	1635	1636	.

O	1637	1640	The
O	1641	1645	data
O	1646	1650	show
O	1651	1655	that
O	1656	1665	letrozole
O	1665	1666	,
O	1667	1668	2
O	1668	1669	.
O	1669	1670	5
O	1671	1673	mg
O	1674	1678	once
O	1679	1684	daily
O	1684	1685	,
O	1686	1688	is
O	1689	1691	as
O	1692	1701	effective
O	1702	1704	in
O	1705	1710	older
O	1710	1711	,
O	1712	1726	postmenopausal
O	1727	1732	women
O	1733	1735	as
O	1736	1738	it
O	1739	1741	is
O	1742	1744	in
O	1745	1752	younger
O	1753	1767	postmenopausal
O	1768	1773	women
O	1774	1778	with
O	1779	1787	advanced
O	1788	1794	breast
O	1795	1801	cancer
O	1801	1802	.

O	1803	1805	In
O	1806	1814	addition
O	1814	1815	,
O	1816	1825	letrozole
O	1826	1829	was
O	1830	1834	more
O	1835	1844	effective
O	1845	1849	than
O	1850	1859	tamoxifen
O	1860	1862	in
O	1863	1867	both
O	1868	1875	younger
O	1876	1879	and
O	1880	1885	older
O	1886	1894	patients
O	1894	1895	.
